

## ProtoADME

ProtoADME is a computational (*in silico*) tool focused on the prediction of endpoints related with the ADME (Absorption, Distribution, Metabolism and Excretion) of chemical substances.

## Endpoint

### Toxicokinetic: CYP450 2C9 inhibitor.

The microsomal cytochrome P450 (CYP) family 4 monooxygenases are the major fatty acid omega-hydroxylases. These enzymes remove excess free fatty acids to prevent lipotoxicity, catabolize leukotrienes and prostanoids, and also produce bioactive metabolites from arachidonic acid omega-hydroxylation. In addition to endogenous substrates, recent evidence indicates that CYP4 monooxygenases can also metabolize xenobiotics, including therapeutic drugs. If a compound is a CYP inhibitor it may decrease the metabolism of comedicated drugs.

## Metrics

### Training set

Experimental values	QSAR predictions	
	Non-inhibitor	Inhibitor
Non-inhibitor	8886	998
Inhibitor	309	5225

### Validation set

Experimental values	QSAR predictions	
	Non-inhibitor	Inhibitor
Non-inhibitor	2016	455
Inhibitor	343	1041

Parameters	Training	Validation
Accuracy	0.92	0.79
Sensitivity / recall	0.94	0.75
Specificity	0.90	0.82
Precision	0.84	0.70
Negative predictive value	0.97	0.85
F-score	0.89	0.72
Matthews Correlation Coefficient	0.82	0.56
Critical Success Index	0.80	0.57
Area under the ROC	0.92	0.78

ProtoADME is part of



ProtoPRED platform allows the easy, fast and user-friendly prediction of different properties of chemical compounds, using proprietary (Q)SAR models.

 +34 962 021 811

 [protopred@protoqsar.com](mailto:protopred@protoqsar.com)

<https://protopred.protoqsar.com/>

©2026 ProtoQSAR S.L.